TRAVERE THERAPEUTICS
Travere Therapeutics is advancing therapeutic candidates for rare disorders in nephrology, hepatology and metabolism; sponsoring no-cost genetic testing aimed at improving the diagnostic odyssey for children born with cholestasis; partnering with patient advocacy organizations to meet the diverse needs of patients and their families; and ensuring broad access and education for its FDA-approved therapies.
TRAVERE THERAPEUTICS
Industry:
Biotechnology Health Care Medical
Founded:
2008-02-07
Address:
San Diego, California, United States
Country:
United States
Website Url:
http://www.travere.com
Total Employee:
101+
Status:
Active
Contact:
(646) 564-3680
Email Addresses:
[email protected]
Total Funding:
942 M USD
Technology used in webpage:
Apple Mobile Web Clips Icon WordPress LetsEncrypt Amazon SSL By Default Mobile Non Scaleable Content IPv6 ReCAPTCHA Google Wordpress Plugins
Similar Organizations
Affimed
Affimed Therapeutics is focused on developing recombinant antibody therapeutics for the treatment of cancer and other diseases.
ArrePath
ArrePath is an anti-infective drug discovery company addressing the global health challenge of drug resistant infections.
Edison Pharmaceuticals
Edison Pharmaceuticals develops medicines for the treatments of children and adults diagnosed with rare and neglected diseases.
F2G
F2G discovers and develops novel drugs for the treatment of life-threatening fungal diseases.
Current Advisors List
Current Employees Featured
Founder
Stock Details
Acquisitions List
| Date | Company | Article | Price |
|---|---|---|---|
| 2020-10-22 | Orphan Technologies | Orphan Technologies acquired by Travere Therapeutics | 517 M USD |
| 2014-02-13 | Manchester Pharmaceuticals | Manchester Pharmaceuticals acquired by Travere Therapeutics | N/A |
Investors List
Athyrium Capital Management LP
Athyrium Capital Management LP investment in Post-IPO Debt - Travere Therapeutics
Athyrium Capital Management LP
Athyrium Capital Management LP investment in Post-IPO Equity - Travere Therapeutics
Investments List
| Date | Company | Article | Money raised |
|---|---|---|---|
| 2014-07-31 | Perlara | Travere Therapeutics investment in Seed Round - Perlara | 2.8 M USD |
Key Employee Changes
| Date | New article |
|---|---|
| 2022-01-04 | Travere Therapeutics Appoints Jula Inrig, M.D., as Chief Medical Officer |
Official Site Inspections
http://www.travere.com Semrush global rank: 1.58 M Semrush visits lastest month: 15.02 K
- Host name: 141.193.213.11
- IP address: 141.193.213.11
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "Travere Therapeutics"
Who We Are | Travere
We are champions of telehealth to streamline optimal access to rare disease care. Travere is a founding sponsor of a telehealth model at Children’s National Rare Disease Institute(CNRDI) in Washington, D.C., to ensure that access to rare disease specialists is not dictated by zip code or mobility. Our work … See moreSee details»
Leadership & Board - Travere
Travere is committed to the principles of workforce development, diversity and inclusion adopted by the Biotechnology Innovation Organization. Learn more about our DEI commitment.See details»
Diversity, Equity, Inclusion & Belonging - Travere
At Travere, we foster a culture that embeds inclusivity in every part of the organization. We work to identify and implement activities aimed at supporting our diversity goals across numerous areas, including: Recruitment, retention and …See details»
Board of Directors | Travere Therapeutics, Inc.
Meckler is the past President and continues to serve on the Board of Children of Bellevue, a non-profit organization focused on advocating and developing pediatric programs at Bellevue …See details»
(State or other jurisdiction of incorporation or organization) (I.R.S ...
Feb 20, 2024 · Certain information contained in this Annual Report on Form 10-K of Travere Therapeutics, Inc., a Delaware corporation (the “Company”) include forward-looking …See details»
Organization | Travere
Travere Report issue. Contributed to NME For profit Phase 1 Phase 2 Phase 3. Founded: San Diego CA United States ... Organization Overview. First Clinical Trial. 2008 NCT00007020. …See details»
Travere Therapeutics Corporate Overview
At Travere Therapeutics, we are a biopharmaceutical company that comes together every day to help patients, families and caregivers of all backgrounds as they navigate life with a rare disease.See details»
OUR BRAND STORY - Travere
To create our brand identity, we brought together team members from across functions, as well as patient advocates and healthcare providers. We shared and explored our views of where we …See details»
Home - Travere Medical Affairs
Find and connect your local Medical Science Liaison (MSL) for support related to Travere products. Have questions? Find scientific, evidence-based and balanced information about Travere products. For more information, please click on the …See details»
Travere Therapeutics Corporate Overview
© 2021 Travere Therapeutics, Inc. Forward-Looking Statements This presentation contains forward-looking statements, including statements about our prospects, products, growth …See details»
Travere Therapeutics - Leadership Team - The Org
The Leadership Team at Travere Therapeutics is responsible for steering the company's strategic direction and ensuring the successful development and delivery of therapies for rare diseases.See details»
Travere Therapeutics: Our Brand Story
To create our brand identity, we brought together team members from across functions, as well as patient advocates and healthcare providers. We shared and explored our views of where we …See details»
Travere Therapeutics to Present at Upcoming Investor Conferences
2 days ago · SAN DIEGO, Nov. 25, 2024 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc., (NASDAQ: TVTX) today announced that company management will present in the following …See details»
Travere Therapeutics Corporate Overview
Travere Therapeutics, we are a biopharmaceutical company that comes together every day to help patients, families, and caregivers of all backgrounds as they navigate life with a rare …See details»
Publications - Travere
Jun 5, 2024 · Below is a bibliography of Travere’s peer-reviewed manuscripts in reverse chronological order. For more information, including poster presentations, and upcoming …See details»
Travere Therapeutics Announces Full FDA Approval of FILSPARI ...
Sep 5, 2024 · Travere Therapeutics has a comprehensive patient support program, Travere TotalCare ®, to enable a smooth experience for patients, their caregivers, and healthcare …See details»
Corporate Privacy Policy - Travere
Nov 14, 2024 · This Privacy Policy generally sets forth Travere Therapeutics’ practices regarding the collection, use and disclosure of personal data and/or information that you may provide …See details»